X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs TTK HEALTHCARE - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH TTK HEALTHCARE STERLING BIOTECH/
TTK HEALTHCARE
 
P/E (TTM) x -0.4 19.3 - View Chart
P/BV x 0.0 2.3 0.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   TTK HEALTHCARE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
TTK HEALTHCARE
Mar-18
STERLING BIOTECH/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs111,458 0.7%   
Low Rs3795 0.4%   
Sales per share (Unadj.) Rs26.8408.7 6.6%  
Earnings per share (Unadj.) Rs-15.012.9 -116.3%  
Cash flow per share (Unadj.) Rs-5.523.6 -23.1%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs54.9164.9 33.3%  
Shares outstanding (eoy) m267.8714.13 1,895.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.32.8 9.4%   
Avg P/E ratio x-0.587.6 -0.5%  
P/CF ratio (eoy) x-1.347.6 -2.7%  
Price / Book Value ratio x0.16.8 1.9%  
Dividend payout %038.9 0.0%   
Avg Mkt Cap Rs m1,86215,916 11.7%   
No. of employees `0001.42.2 60.3%   
Total wages/salary Rs m5471,090 50.2%   
Avg. sales/employee Rs Th5,303.32,573.8 206.1%   
Avg. wages/employee Rs Th403.8485.7 83.1%   
Avg. net profit/employee Rs Th-2,959.081.0 -3,654.4%   
INCOME DATA
Net Sales Rs m7,1815,776 124.3%  
Other income Rs m4376 56.3%   
Total revenues Rs m7,2235,851 123.4%   
Gross profit Rs m947426 222.5%  
Depreciation Rs m2,543152 1,668.8%   
Interest Rs m4,37747 9,253.9%   
Profit before tax Rs m-5,931302 -1,967.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924120 -1,606.3%   
Profit after tax Rs m-4,007182 -2,205.0%  
Gross profit margin %13.27.4 179.0%  
Effective tax rate %32.439.7 81.7%   
Net profit margin %-55.83.1 -1,773.5%  
BALANCE SHEET DATA
Current assets Rs m14,3352,556 560.8%   
Current liabilities Rs m49,8091,675 2,973.3%   
Net working cap to sales %-494.015.3 -3,239.0%  
Current ratio x0.31.5 18.9%  
Inventory Days Days40333 1,206.5%  
Debtors Days Days17135 487.9%  
Net fixed assets Rs m55,4321,103 5,024.9%   
Share capital Rs m268141 189.6%   
"Free" reserves Rs m13,9352,188 636.8%   
Net worth Rs m14,7012,330 631.0%   
Long term debt Rs m9,4787 143,603.8%   
Total assets Rs m73,9884,073 1,816.6%  
Interest coverage x-0.47.4 -4.8%   
Debt to equity ratio x0.60 22,756.8%  
Sales to assets ratio x0.11.4 6.8%   
Return on assets %0.55.6 8.9%  
Return on equity %-27.37.8 -349.4%  
Return on capital %-6.414.9 -43.0%  
Exports to sales %25.93.0 869.7%   
Imports to sales %0.20.6 28.3%   
Exports (fob) Rs m1,860172 1,081.3%   
Imports (cif) Rs m1235 35.2%   
Fx inflow Rs m1,860172 1,081.3%   
Fx outflow Rs m2555 45.1%   
Net fx Rs m1,835117 1,570.3%   
CASH FLOW
From Operations Rs m1,719253 679.3%  
From Investments Rs m-3,148-226 1,395.5%  
From Financial Activity Rs m1,426-72 -1,980.6%  
Net Cashflow Rs m-3-41 8.3%  

Share Holding

Indian Promoters % 33.9 65.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 3.7 -  
FIIs % 9.9 5.2 190.4%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 25.8 152.3%  
Shareholders   21,482 12,723 168.8%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 43.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, TTK HEALTHCARE has posted a net profit of Rs 80 m (up 43.1% YoY). Sales on the other hand came in at Rs 1 bn (up 21.4% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - ALEMBIC PHARMA COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS